Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Galectin Therapeutics ( (GALT) ).
On July 8, 2025, Galectin Therapeutics secured a $10 million line of credit from Richard E. Uihlein to support its working capital needs, with the option to convert the debt into company stock. This financing, expected to cover expenditures through June 2026, underscores Uihlein’s commitment to the company’s MASH cirrhosis program and positions Galectin to continue its development efforts and seek partnerships for belapectin. Additionally, the company announced employee compensation strategies, including bonuses contingent on partnership agreements for belapectin and retention bonuses for key executives.
The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.
Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Galectin Therapeutics is a biopharmaceutical company focused on developing novel therapies for chronic liver diseases and cancer. Its lead drug, belapectin, targets the galectin-3 protein and is primarily aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis. The company is also exploring treatments for advanced head and neck cancers and other malignancies.
Average Trading Volume: 597,890
Technical Sentiment Signal: Buy
Current Market Cap: $136.1M
See more data about GALT stock on TipRanks’ Stock Analysis page.